NCT05398952: POSTCOV

Post-COVID-19 Outpatient Care and Biomarkers

Status unknown Last updated 8 June 2022

What this trial tests

trial testing Laboratory investigations in Post Viral Fatigue in 2,000 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Medical University of Vienna
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 April 2021
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across Austria

Drugs / interventions tested

• Laboratory investigations

Conditions studied

• Post Viral Fatigue — all drugs for Post Viral Fatigue →
• Viral Myocarditis — all drugs for Viral Myocarditis →
• POTS — all drugs for POTS →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 90, any sex, with Post Viral Fatigue or Viral Myocarditis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this case-control, non-randomized study including patients with post-COVID-19 persisting symptoms are 1) to establish the large blood biobank, 2) to examine levels of circulating inflammatory biomarkers and different classes of non-coding RNAs (ncRNA), such as selected circRNAs and miRNAs, in plasma and serum samples collected from patients with post- COVID-19, 3) to test the levels of cfDNA in plasma and serum, 4) to define correlation between ncRNAs and cf-DNA with persistent clinical symptoms, and type of symptoms, and 5) to investigate diagnostic and prognostic performances of these circulating biomarkers.

Study design. This is a prospective registry including biobank.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Postural Orthostatic Tachycardia Syndrome in COVID-19: A Contemporary Review of Mechanisms, Clinical Course and Management.
   Narasimhan B, Calambur A, Moras E, Wu L, et al · · 2023 · cited 14× · PMID 37204997 · DOI 10.2147/vhrm.s380270
2. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.
   Gyöngyösi M, Lukovic D, Mester-Tonczar J, Zlabinger K, et al · · 2023 · cited 6× · PMID 37773184 · DOI 10.1038/s41541-023-00739-2
3. Impact of Circulating Anti-Spike Protein Antibody Levels on Multi-Organ Long COVID Symptoms.
   Hamzaraj K, Han E, Hasimbegovic E, Poschenreiter L, et al · · 2024 · cited 3× · PMID 38932339 · DOI 10.3390/vaccines12060610
4. Improvement of Symptoms and Cardiac Magnetic Resonance Abnormalities in Patients with Post-Acute Sequelae of SARS-CoV-2 Cardiovascular Syndrome (PASC-CVS) after Guideline-Oriented Therapy.
   Gyöngyösi M, Hasimbegovic E, Han E, Zlabinger K, et al · · 2023 · cited 3× · PMID 38137533 · DOI 10.3390/biomedicines11123312
5. Circulating Autoantibodies Against Vasoactive Biomarkers Related to Orthostatic Intolerance in Long COVID Patients Compared to No-Long-COVID Populations: A Case-Control Study.
   Han E, Müller-Zlabinger K, Hasimbegovic E, Poschenreithner L, et al · · 2025 · cited 2× · PMID 40001603 · DOI 10.3390/biom15020300
6. Improvement of clinical symptoms and cardiac abnormalities detected by cardiac magnetic resonance imaging in patients with long COVID syndrome after guideline-oriented therapy
   Pavone-Gyöngyösi M, Hasimbegovic E, Lukovic D, han E, et al · · 2023 · DOI 10.21203/rs.3.rs-3079339/v1
7. Interruption of viral interference by anti-SARS-CoV-2 vaccination
   Gyöngyösi M, Lukovic D, Tonczar JM, Zlabinger K, et al · · 2023 · DOI 10.21203/rs.3.rs-2627410/v1